Table 1.
Patient characteristics.
| Variables | Responder | Non-Responder | p |
|---|---|---|---|
| Number | 53 | 107 | |
| Age (year, median, IQR) | 72 (70–78) | 72 (68–78) | 0.707 |
| Sex (n, %) | 0.845 | ||
| Male | 41 (77.4) | 80 (74.8) | |
| Female | 12 (22.6) | 27 (25.2) | |
| BMI (kg/m2, median, IQR) | 22.2 (19.4–24.2) | 22.0 (19.5–24.5) | 0.988 |
| ECOG-PS | |||
| 0 | 38 (71.7) | 56 (52.3) | 0.026 |
| 1 | 12 (22.6) | 29 (27.1) | |
| 2 | 1 (1.9) | 16 (15.0) | |
| 3 | 2 (3.8) | 6 (5.6) | |
| Primary site (number, %) | 0.485 | ||
| Upper urinary tract | 19 (35.8) | 30 (28.0) | |
| Bladder | 26 (49.1) | 63 (58.9) | |
| Upper urinary tract and Bladder | 8 (15.1) | 14 (13.1) | |
| Location of metastases (number, %) | |||
| Lung | 13 (24.5) | 53 (49.5) | 0.004 |
| Liver | 5 (9.4) | 23 (21.5) | 0.077 |
| Bone | 5 (9.4) | 25 (23.4) | 0.051 |
| Lymph node | 36 (67.9) | 80 (74.8) | 0.452 |
| Smoking history (number, %) | |||
| Never | 18 (34.0) | 43 (40.2) | 0.239 |
| Current | 5 (9.4) | 18 (16.8) | |
| Former | 30 (56.6) | 46 (43.0) | |
| Definitive therapy for primary site (number, %) | 47 (88.7) | 83 (77.6) | 0.131 |
| Histological subtype (number, %) | 0.322 | ||
| Pure urothelial carcinoma | 43 (82.7) | 95 (88.8) | |
| Sarcomatoid variant | 3 (5.7) | 3 (2.8) | |
| other variants | 7 (13.2) | 9 (17.3) | |
| Follow-up period | 19 (12–26) | 6 (3–13) | <0.001 |
| (months, median, IQR) |
IQR, interquartile range; ECOG-PS, Eastern Cooperative Oncology Group performance status.